Metastatic breast cancer - Overview of treatment
Metastatic breast cancer - Overview of treatment
复制标题
DOI：
10.1097/01.blo.0000092981.12414.7b
复制
发表时间：
2003-10-01
影响因子：
4.2
通讯作者：
Lipton, A
中科院分区：
文献类型：
--
作者：
Ali, SM;Harvey, HA;Lipton, A
转移性乳腺癌患者的中位生存期为2至3年。只有骨转移的患者中有20%在诊断后5年内存活。目前的治疗旨在改善生活质量，症状控制和延长生存期。较新的内分泌和化疗药物可用于治疗转移性乳腺癌患者的医疗肿瘤学家。我们将简要回顾转移性乳腺癌治疗的新进展。
Patients with metastatic breast cancer have a median survival of 2 to 3 years. Twenty percent of the patients who present with bone-only metastasis will be alive at 5 years from diagnosis. Current therapies are aimed at improving the quality of life, symptom control, and prolongation of survival. Newer endocrine and chemotherapeutic drugs are available to the medical oncologist for care of patients with metastatic breast cancer. We will briefly review the new advances in the treatment of metastatic breast cancer.